Erratum: The role of CD95 and CD95 ligand in cancer (Cell Death and Differentiation (2015) 22 (549-559) (DOI: 10.1038/cdd.2015.3));The role of CD95 and CD95 ligand in cancer

Cell Death and Differentiation

Volumn 22, Issue 4, 2015, Pages 549-559

  Peter, M E ^a   Hadji, A ^a,b   Murmann, A E ^a   Brockway, S ^a   Putzbach, W ^a   Pattanayak, A ^a   Ceppi, P ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APOPTOSIS INDUCING FACTOR; FAS ANTIGEN; FAS LIGAND; PROGRAMMED DEATH 1 RECEPTOR INHHIBITOR; PROGRAMMED DEATH LIGAND 1 INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CELL KILLING; DRUG EFFICACY; DRUG TARGETING; HUMAN; IMMUNE SYSTEM; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL FACTOR; TUMOR IMMUNITY; TUMOR PROMOTION; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; RNA INTERFERENCE;

ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; IMMUNE SYSTEM; NEOPLASMS; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84925515692     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.25     Document Type: Erratum

References (182)

1. Nagata S. Apoptosis by death factor. Cell 1997; 88: 355-365.
2. Krammer PH. CD95's deadly mission in the immune system. Nature 2000; 407: 789-795.
3. Peter ME, Barnhart BC, Algeciras-Schimnich A. The Cytokine Handbook: CD95L/FasL and its receptor CD95 (APO-1/Fas). Cytokine Handb 2003; 2: 885-911.
4. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992; 356: 314-317.
5. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T et al. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994; 76: 969-976.
6. Adachi M, Suematsu S, Kondo T, Ogasawara J, Tanaka T, Yoshida N et al. Targeted mutation in the Fas gene causes hyperplasia in peripheral lymphoid organs and liver. Nat Genet 1995; 11: 294-300.
7. Karray S, Kress C, Cuvellier S, Hue-Beauvais C, Damotte D, Babinet C et al. Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele. J Immunol 2004; 172: 2118-2125.
8. Senju S, Negishi I, Motoyama N, Wang F, Nakayama K, Lucas PJ et al. Functional significance of the Fas molecule in naive lymphocytes. Int Immunol 1996; 8: 423-431.
9. Kimura M, Matsuzawa A. Autoimmunity in mice bearing lprcg: a novel mutant gene. Int Rev Immunol 1994; 11: 193-210.
10. Bidere N, Su HC, Lenardo MJ. Genetic disorders of programmed cell death in the immune system. Annu Rev Immunol 2006; 24: 321-352.
11. Siegel RM, Frederiksen JK, Zacharias DA, Chan FK, Johnson M, Lynch D et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000; 288: 2354-2357.
12. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME. Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 2002; 22: 207-220.
13. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ 2003; 10: 26-35.
14. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 1997; 16: 2794-2804.
15. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen KJ et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994; 369: 31-37.
16. Braun MY, Lowin B, French L, Acha-Orbea H, Tschopp J. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versus-host disease. J Exp Med 1996; 183: 657-661.
17. Winter H, Hu HM, Urba WJ, Fox BA. Tumor regression after adoptive transfer of effector T cells is independent of perforin or Fas ligand (APO-1L/CD95L). J Immunol 1999; 163: 4462-4472.
18. Qin Z, Schwartzkopff J, Pradera F, Kammertoens T, Seliger B, Pircher H et al. A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. Cancer Res 2003; 63: 4095-4100.
19. Bohm W, Thoma S, Leithauser F, Moller P, Schirmbeck R, Reimann J. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol 1998; 161: 897-908.
20. Wigginton JM, Gruys E, Geiselhart L, Subleski J, Komschlies KL, Park JW et al. IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest 2001; 108: 51-62.
21. Kowalczyk DW, Wlazlo AP, Giles-Davis W, Kammer AR, Mukhopadhyay S, Ertl HC. Vaccine-induced CD8+ T cells eliminate tumors by a two-staged attack. Cancer Gene Ther 2003; 10: 870-878.
22. Barth Jr RJ, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med 1991; 173: 647-658.
23. Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol 2000; 164: 3645-3651.
24. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 1994; 370: 650-652.
25. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S et al. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
26. Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Ohno H et al. Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1994; 1: 357-364.
27. Rouvier E, Luciani MF, Golstein P. Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity. J Exp Med 1993; 177: 195-200.
28. Stalder T, Hahn S, Erb P. Fas antigen is the major target molecule for CD4+ T cell-mediated cytotoxicity. J Immunol 1994; 152: 1127-1133.
29. Ju ST, Cui H, Panka DJ, Ettinger R, Marshak-Rothstein A. Participation of target Fas protein in apoptosis pathway induced by CD4+ Th1 and CD8+ cytotoxic T cells. Proc Natl Acad Sci USA 1994; 91: 4185-4189.
30. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-495.
31. Karl I, Jossberger-Werner M, Schmidt N, Horn S, Goebeler M, Leverkus M et al. TRAF2 inhibits TRAIL- and CD95L-induced apoptosis and necroptosis. Cell Death Dis 2014; 5: e1444.
32. Algeciras-Schimnich A, Pietras EM, Barnhart BC, Legembre P, Vijayan S, Holbeck SL et al. Two CD95 tumor classes with different sensitivities to antitumor drugs. Proc Natl Acad Sci USA 2003; 100: 11445-11450.
33. Ivanov VN, Lopez Bergami P, Maulit G, Sato TA, Sassoon D, Ronai Z. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003; 23: 3623-3635.
34. Ivanov VN, Ronai Z, Hei TK. Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem 2006; 281: 1840-1852.
35. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195.
36. Tourneur L, Mistou S, Michiels FM, Devauchelle V, Renia L, Feunteun J et al. Loss of FADD protein expression results in a biased Fas-signaling pathway and correlates with the development of tumoral status in thyroid follicular cells. Oncogene 2003; 22: 2795-2804.
37. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001; 20: 5865-5877.
38. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000; 6: 529-535.
39. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002; 2: 277-288.
40. Peter ME, Budd RC, Desbarats J, Hedrick SM, Hueber AO, Newell MK et al. The CD95 receptor: apoptosis revisited. Cell 2007; 129: 447-450.
41. Peter ME, Legembre P, Barnhart BC. Does CD95 have tumor promoting activities? Biochim Biophys Acta 2005; 1755: 25-36.
42. Martin-Villalba A, Llorens-Bobadilla E,Wollny D. CD95 in cancer: tool or target? Trends Mol Med 2013; 19: 329-335.
43. Wajant H, Pfizenmaier K, Scheurich P. Non-apoptotic Fas signaling. Cytokine Growth Factor Rev 2003; 14: 53-66.
44. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C et al. CD95 promotes tumour growth. Nature 2010; 465: 492-496.
45. Desbarats J, Newell MK. Fas engagement accelerates liver regeneration after partial hepatectomy. Nat Med 2000; 6: 920-923.
46. Jarad G, Wang B, Khan S, DeVore J, Miao H, Wu K et al. Fas activation induces renal tubular epithelial cell beta 8 integrin expression and function in the absence of apoptosis. J Biol Chem 2002; 277: 47826-47833.
47. Reinehr R, Sommerfeld A, Haussinger D. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells. Gastroenterol 2008; 134: 1494-1506.
48. Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS, Newell MK. Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 2003; 5: 118-125.
49. Zuliani C, Kleber S, Klussmann S, Wenger T, Kenzelmann M, Schreglmann N et al. Control of neuronal branching by the death receptor CD95 (Fas/Apo-1). Cell Death Differ 2006; 13: 31-40.
50. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet 1999; 33: 29-55.
51. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009; 30: 180-192.
52. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
53. Igney FH, Behrens CK, Krammer PH. Tumor counterattack-concept and reality. Eur J Immunol 2000; 30: 725-731.
54. Chappell DB, Restifo NP. T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother 1998; 47: 65-71.
55. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-1082.
56. Igney FH, Krammer PH. Tumor counterattack: fact or fiction? Cancer Immunol Immunother 2005; 54: 1127-1136.
57. Yu JS, Lee PK, Ehtesham M, Samoto K, Black KL, Wheeler CJ. Intratumoral T cell subset ratios and Fas ligand expression on brain tumor endothelium. J Neurooncol 2003; 64: 55-61.
58. Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM et al. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008; 14: 324-334.
59. Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS et al. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 2014; 20: 607-615.
60. Alderson MR, Armitage RJ, Maraskovsky E, Tough TW, Roux E, Schooley K et al. Fas transduces activation signals in normal human T lymphocytes. J Exp Med 1993; 178: 2231-2235.
61. Kennedy NJ, Kataoka T, Tschopp J, Budd RC. Caspase activation is required for T cell proliferation. J Exp Med 1999; 190: 1891-1896.
62. Alam A, Cohen LY, Aouad S, Sekaly RP. Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells. J Exp Med 1999; 190: 1879-1890.
63. Ichikawa K, Yoshida-Kato H, Ohtsuki M, Ohsumi J, Yamaguchi J, Takahashi S et al. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000; 12: 555-562.
64. Barnhart BC, Legembre P, Pietras E, Bubici C, Franzoso G, Peter ME. CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. EMBO J 2004; 23: 3175-3185.
65. Legembre P, Barnhart BC, Zheng L, Vijayan S, Straus SE, Puck J et al. Induction of apoptosis and activation of NF-kappaB by CD95 require different signalling thresholds. EMBO Rep 2004; 5: 1084-1089.
66. Legembre P, Barnhart BC, Peter ME. The Relevance of NF-kappaB for CD95 Signaling in Tumor Cells. Cell Cycle 2004; 3: 1235-1239.
67. Legembre P, Schickel R, Barnhart BC, Peter ME. Identification of SNF1/AMP Kinase-related Kinase as an NF-{kappa}B-regulated Anti-apoptotic Kinase Involved in CD95-induced Motility and Invasiveness. J Biol Chem 2004; 279: 46742-46747.
68. Lee JK, Sayers TJ, Back TC, Wigginton JM, Wiltrout RH. Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer. Apoptosis 2003; 8: 151-160.
69. Zhang Y, Liu Q, Zhang M, Yu Y, Liu X, Cao X. Fas signal promotes lung cancer growth by recruiting myeloid-derived suppressor cells via cancer cell-derived PGE2. J Immunol 2009; 182: 3801-3808.
70. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterol 2010; 138: 2357-2367.
71. Park SM, Chen L, Zhang M, Ashton-Rickardt P, Turner JR, Peter ME. CD95 is cytoprotective for intestinal epithelial cells in colitis. Inflamm Bowel Dis 2010; 16: 1063-1070.
72. Yuan K, Jing G, Chen J, Liu H, Zhang K, Li Y et al. Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK). J Biol Chem 2011; 286: 24776-24784.
73. Trauzold A, Roder C, Sipos B, Karsten K, Arlt A, Jiang P et al. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J 2005; 19: 620-622.
74. Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O et al. Yes and PI3K Bind CD95 to Signal Invasion of Glioblastoma. Cancer Cell 2008; 13: 235-248.
75. Nijkamp MW, Hoogwater FJ, Steller EJ, Westendorp BF, van der Meulen MW, Rinkes IH et al. CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation. J Hepatol 2010; 53: 1069-1077.
76. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213.
77. Tanaka M, Itai T, Adachi M, Nagata S. Downregulation of Fas ligand by shedding. Nat Med 1998; 4: 31-36.
78. La OR, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461: 659-663.
79. Bivona TG, Hieronymus H, Parker J, Chang K, Taron M, Rosell R et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011; 471: 523-526.
80. Tauzin S, Chaigne-Delalande B, Selva E, Khadra N, Daburon S, Contin-Bordes C et al. The naturally processed CD95L elicits a c-yes/calcium/PI3K-driven cell migration pathway. PLoS Biol 2011; 9: e1001090.
81. Steller EJ, Ritsma L, Raats DA, Hoogwater FJ, Emmink BL, Govaert KM et al. The death receptor CD95 activates the cofilin pathway to stimulate tumour cell invasion. EMBO Rep 2011; 12: 931-937.
82. Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F et al. CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Cancer Res 2013; 73: 6711-6721.
83. Teodorczyk M, Kleber S, Wollny D, Sefrin JP, Aykut B, Mateos A et al. CD95 promotes metastatic spread via Sck in pancreatic ductal adenocarcinoma. Cell Death Differ 2015; e-pub ahead of print 23 January 2015; doi:10.1038/cdd.2014.217.
84. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11: 63-70.
85. Chan KW, Lee PY, Lam AK, Law S, Wong J, Srivastava G. Clinical relevance of Fas expression in oesophageal squamous cell carcinoma. J Clin Pathol 2006; 59: 101-104.
86. Kojima Y, Tsurumi H, Goto N, Shimizu M, Kasahara S, Yamada T et al. Fas and Fas ligand expression on germinal center type-diffuse large B-cell lymphoma is associated with the clinical outcome. Eur J Haematol 2006; 76: 465-472.
87. Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005; 93: 544-551.
88. Eser B, Sari I, Canoz O, Altuntas F, Cakmak E, Ozturk A et al. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma. Am J Hematol 2006; 81: 307-314.
89. Chatzitolios A, Venizelos I, Tripsiannis G, Anastassopoulos G, Papadopoulos N. Prognostic significance of CD95, P53, and BCL2 expression in extranodal non-Hodgkin's lymphoma. Ann Hematol 2010; 89: 889-896.
90. de Carvalho-Neto PB, dos Santos M, de Carvalho MB, Mercante AM, dos Santos VP, Severino P et al. FAS/FASL expression profile as a prognostic marker in squamous cell carcinoma of the oral cavity. PLoS One 2013; 8: e69024.
91. Strater J, Hinz U, Hasel C, Bhanot U, Mechtersheimer G, Lehnert T et al. Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease. Gut 2005; 54: 661-665.
92. Asensio C, Zapata A, Garcia-Ahijado J, Gil B, Salvadores P, Schneider J. Fas expression is associated with a better prognosis in laryngeal squamous cell carcinoma. Anticancer Res 2007; 27: 4083-4086.
93. Koomagi R, Volm M. Expression of Fas (CD95/APO-1) and Fas ligand in lung cancer, its prognostic and predictive relevance. Int J Cancer 1999; 84: 239-243.
94. Shibakita M, Tachibana M, Dhar DK, Kotoh T, Kinugasa S, Kubota H et al. Prognostic significance of Fas and Fas ligand expressions in human esophageal cancer. Clin Cancer Res 1999; 5: 2464-2469.
95. Baryshnikov A, Polosukhina ER, Tupitsin NN, Gavrikova NV, Andreeva L, Zabotina TN et al. CD95 (FAS/APO-1) antigen is a new prognostic marker of blast cells of acute lymphoblastic leukaemia patients. Adv Exp Med Biol 1999; 457: 251-258.
96. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T et al. Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 1999; 35: 1462-1465.
97. Kase S, Osaki M, Adachi H, Kaibara N, Ito H. Expression of Fas and Fas ligand in esophageal tissue mucosa and carcinomas. Int J Oncol 2002; 20: 291-297.
98. Volm M, Koomagi R, Mattern J, Efferth T. Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin Cancer Res 2002; 8: 1843-1848.
99. Bernstorff WV, Glickman JN, Odze RD, Farraye FA, Joo HG, Goedegebuure PS et al. Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors. Implications for immune privilege and immune escape. Cancer 2002; 94: 2552-2560.
100. Fokkema E, Timens W, de Vries EG, de Jong S, Fidler V, Meijer C et al. Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer 2006; 52: 241-247.
101. Fathi M, Amirghofran Z, Shahriari M. Soluble Fas and Fas ligand and prognosis in children with acute lymphoblastic leukemia. Med Onc 2012; 29: 2046-2052.
102. Charafe-Jauffret E, Ginestier C, Birnbaum D. Breast cancer stem cells: tools and models to rely on. BMC Cancer 2009; 9: 202.
103. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
104. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 2009; 106: 13820-13825.
105. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120: 41-50.
106. Gupta PB, Chaffer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med 2009; 15: 1010-1012.
107. Corsini NS, Sancho-Martinez I, Laudenklos S, Glagow D, Kumar S, Letellier E et al. The death receptor CD95 activates adult neural stem cells for working memory formation and brain repair. Cell Stem Cell 2009; 5: 178-190.
108. Richards M, Tan SP, Tan JH, Chan WK, Bongso A. The transcriptome profile of human embryonic stem cells as defined by SAGE. Stem Cells 2004; 22: 51-64.
109. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA et al. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 2007; 104: 11400-11405.
110. Hau A, Ceppi P, Peter ME. CD95 Is Part of a let-7/p53/miR-34 Regulatory Network. PLoS One 2012; 7: e49636.
111. Zheng H, Li W, Wang Y, Xie T, Cai Y, Wang Z et al. miR-23a inhibits E-cadherin expression and is regulated by AP-1 and NFAT4 complex during Fas-induced EMT in gastrointestinal cancer. Carcinogenesis 2014; 35: 173-183.
112. Zheng HX, Cai YD, Wang YD, Cui XB, Xie TT, Li WJ et al. Fas signaling promotes motility and metastasis through epithelial-mesenchymal transition in gastrointestinal cancer. Oncogene 2013; 32: 1183-1192.
113. Zheng H, Li W, Wang Y, Liu Z, Cai Y, Xie T et al. Glycogen synthase kinase-3 beta regulates Snail and beta-catenin expression during Fas-induced epithelial-mesenchymal transition in gastrointestinal cancer. Eur J Cancer 2013; 49: 2734-2746.
114. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al. The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
115. Ceppi P, Hadji A, Kohlhapp F, Pattanayak A, Hau A, Xia L et al. CD95 and CD95L promote and protect cancer stem cells. Nat Commun 2014; 5: 5238.
116. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors, ZEB1 and ZEB2. Genes Dev 2008; 22: 894-907.
117. Shimono Y, Zabala M, Cho RW, Lobo N, Dalerba P, Qian D et al. Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. Cell 2009; 138: 592-603.
118. Schickel R, Park SM, Murmann AE, Peter ME. mir-200c regulates induction of apoptosis through CD95 by targeting FAP-1. Mol Cell 2010; 38: 908-915.
119. Hadji A, Ceppi P, Murmann AE, Brockway S, Pattanayak A, Bhinder B et al. Death induced by CD95 or CD95 ligand elimination. Cell Rep 2014; 10: 208-222.
120. Peter ME. DICE: A novel tumor surveillance mechanism - a new therapy for cancer? Cell Cycle 2014; 13: 1373-1378.
121. Friesen C, Fulda S, Debatin KM. Cytotoxic drugs and the CD95 pathway. Leukemia 1999; 13: 1854-1858.
122. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42-49.
123. Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong C et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007; 131: 1109-1123.
124. Visvader JE, Lindeman GJ. Cancer stem cells: current status and evolving complexities. Cell Stem Cell 2012; 10: 717-728.
125. Ametller E, Garcia-Recio S, Costamagna D, Mayordomo C, Fernandez-Nogueira P, Carbo N et al. Tumor promoting effects of CD95 signaling in chemoresistant cells. Mol Cancer 2010; 9: 161.
126. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012; 366: 2455-2465.
127. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
128. Lipson EJ, Sharfman WH, Drake CG,Wollner I, Taube JM, Anders RA et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res 2013; 19: 462-468.
129. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013; 369: 134-144.
130. Konno R, Takano T, Sato S, Yajima A. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies. Clin Cancer Res 2000; 6: 3576-3580.
131. Osorio LM, Aguilar-Santelises M, De Santiago A, Hachiya T, Mellstedt H, Jondal M. Increased serum levels of soluble Fas in progressive B-CLL. Eur J Haematol 2001; 66: 342-346.
132. Muschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J et al. CD95 ligand expression in dedifferentiated breast cancer. J Pathol 1999; 189: 378-386.
133. Mizutani Y, Hongo F, Sato N, Ogawa O, Yoshida O, Miki T. Significance of serum soluble Fas ligand in patients with bladder carcinoma. Cancer 2001; 92: 287-293.
134. Mizutani Y, Yoshida O, Ukimura O, Kawauchi A, Bonavida B, Miki T. Prognostic significance of a combination of soluble Fas and soluble Fas ligand in the serum of patients with Ta bladder cancer. Cancer Biother Radiopharm 2002; 17: 563-567.
135. Chopin D, Barei-Moniri R,Maille P, Le Frere-Belda MA,Muscatelli-Groux B, Merendino N et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 2003; 162: 1139-1149.
136. Yang H, Li H, Wang Z, Gao J, Guo Y. Is urinary soluble Fas an independent predictor of non-muscle-invasive bladder cancer? A prospective chart study. Urol Int 2013; 91: 456-461.
137. Gutierrez LS, Eliza M, Niven-Fairchild T, Naftolin F, Mor G. The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat 1999; 54: 245-253.
138. Mottolese M, Buglioni S, Bracalenti C, Cardarelli MA, Ciabocco L, Giannarelli D et al. Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer 2000; 89: 127-132.
139. Reimer T, Herrnring C, Koczan D, Richter D, Gerber B, Kabelitz D et al. FasL:Fas ratio - a prognostic factor in breast carcinomas. Cancer Res 2000; 60: 822-828.
140. Mullauer L, Mosberger I, Grusch M, Rudas M, Chott A. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer. J Pathol 2000; 190: 20-30.
141. Bewick M, Conlon M, Parissenti AM, Lee H, Zhang L, Gluck S et al. Soluble Fas (CD95) is a prognostic factor in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous stem cell transplantation. J Hematother Stem Cell Res 2001; 10: 759-768.
142. Munakata S, Watanabe O, Ohashi K, Morino H. Expression of Fas ligand and bcl-2 in cervical carcinoma and their prognostic significance. Am J Clin Pathol 2005; 123: 879-885.
143. Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer 2001; 85: 1047-1054.
144. Wu SF, Zhang JW, Qian WY, Yang YB, Liu Y, Dong Y et al. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci 2012; 16: 2044-2050.
145. Lerma E, Romero M, Gallardo A, Pons C, Munoz J, Fuentes J et al. Prognostic significance of the Fas-receptor/Fas-ligand system in cervical squamous cell carcinoma. Virchows Arch 2008; 452: 65-74.
146. Mann B, Gratchev A, Bohm C, Hanski ML, Foss HD, Demel G et al. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer 1999; 79: 1262-1269.
147. Belluco C, Esposito G, Bertorelle R, Alaggio R, Giacomelli L, Bianchi LC et al. Fas ligand is up-regulated during the colorectal adenoma-carcinoma sequence. Eur J Surg Oncol 2002; 28: 120-125.
148. Nozoe T, Yasuda M, Honda M, Inutsuka S, Korenaga D. Fas ligand expression is correlated with metastasis in colorectal carcinoma. Oncology 2003; 65: 83-88.
149. Zhang W, Ding EX, Wang Q, Zhu DQ, He J, Li YL et al. Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol 2005; 11: 3632-3635.
150. Li H, Fan X, Stoicov C, Liu JH, Zubair S, Tsai E et al. Human and mouse colon cancer utilizes CD95 signaling for local growth and metastatic spread to liver. Gastroenterol 2009; 137: 934-944.
151. Hoogwater FJ, Snoeren N, Nijkamp MW, Gunning AC, van Houdt WJ, de Bruijn MT et al. Circulating CD95-ligand as a potential prognostic marker for recurrence in patients with synchronous colorectal liver metastases. Anticancer Res 2011; 31: 4507-4512.
152. Kykalos S, Mathaiou S, Karayiannakis AJ, Patsouras D, Lambropoulou M, Simopoulos C. Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases. J Gastrointest Cancer 2012; 43: 224-228.
153. Saigusa S, Tanaka K, Ohi M, Toiyama Y, Yasuda H, Kitajima T et al. Clinical implications of Fas/Fas ligand expression in patients with esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy. Mol Clin Oncol 2015; 3: 151-156.
154. Tsutsumi S, Kuwano H, Shimura T, Morinaga N, Mochiki E, Asao T. Circulating soluble Fas ligand in patients with gastric carcinoma. Cancer 2000; 89: 2560-2564.
155. Ichikura T, Majima T, Uchida T, Okura E, Ogawa T, Mochizuki H. Plasma soluble Fas ligand concentration: decrease in elderly men and increase in patients with gastric carcinoma. Oncol Rep 2001; 8: 311-314.
156. Nagashima H, Mori M, Sadanaga N, Mashino K, Yoshikawa Y, Sugimachi K. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis. Int J Oncol 2001; 18: 1157-1162.
157. Osaki M, Kase S, Kodani I, Watanabe M, Adachi H, Ito H. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis. Gastric Cancer 2001; 4: 198-205.
158. Zheng HC, Sun JM, Wei ZL, Yang XF, Zhang YC, Xin Y. Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer. World J Gastroenterol 2003; 9: 1415-1420.
159. Nada O, Abdel-Hamid M, Ismail A, El Shabrawy L, Sidhom KF, El Badawy NM et al. The role of the tumor necrosis factor (TNF)-Fas L and HCV in the development of hepatocellular carcinoma. J Clin Virol 2005; 34: 140-146.
160. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F et al. Fas ligand in human serum. Nat Med 1996; 2: 317-322.
161. El Bassiouny AE, El-Bassiouni NE, Nosseir MM, Zoheiry MM, El-Ahwany EG, Salah F et al. Circulating and hepatic Fas expression in HCV-induced chronic liver disease and hepatocellular carcinoma. Medscape J Med 2008; 10: 130.
162. Abrahams VM, Straszewski SL, Kamsteeg M, Hanczaruk B, Schwartz PE, Rutherford TJ et al. Epithelial ovarian cancer cells secrete functional Fas ligand. Cancer Res 2003; 63: 5573-5581.
163. Munakata S, Enomoto T, Tsujimoto M, Otsuki Y, Miwa H, Kanno H et al. Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer 2000; 82: 1446-1452.
164. Taylor DD, Lyons KS, Gercel-Taylor C. Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol 2002; 84: 443-448.
165. Chaudhry P, Srinivasan R, Patel FD, Gopalan S, Majumdar S. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer. Int J Cancer 2008; 122: 1716-1721.
166. Bellone G, Smirne C, Carbone A, Mareschi K, Dughera L, Farina EC et al. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma. Clin Cancer Res 2000; 6: 2448-2455.
167. Hazar V, Berber Z, Pestereli E, Coskun M, Yesilipek A, Karpuzoglu G et al. Clinical importance of circulating and cellular expression levels of Fas and Fas ligand in pediatric patients with lymphoproliferative malignancies. Pediatr Hematol Oncol 2005; 22: 247-256.
168. Macher-Goeppinger S, Bermejo JL, Wagener N, Hohenfellner M, Haferkamp A, Schirmacher P et al. Expression and prognostic relevance of the death receptor CD95 (Fas/APO1) in renal cell carcinomas. Cancer Lett 2011; 301: 203-211.
169. Somma P, Lo Muzio L, Mansueto G, Delfino M, Fabbrocini G, Mascolo M et al. Squamous cell carcinoma of the lower lip: FAS/FASL expression, lymphocyte subtypes and outcome. Int J Immunopathol Pharmacol 2005; 18: 59-64.
170. Sejima T, Morizane S, Hinata N, Yao A, Isoyama T, Saito M et al. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy. Urol Int 2012; 88: 263-270.
171. Muraki Y, Tateishi A, Seta C, Fukuda J, Haneji T, Oya R et al. Fas antigen expression and outcome of oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2000; 29: 360-365.
172. Fang L, Sun L, Hu FF, Chen QE. Effects of FasL expression in oral squamous cell cancer. Asian Pac J Cancer Prev 2013; 14: 281-285.
173. Hara S, Miyake H, Nakamura I, Arakawa S, Kamidono S, Hara I. Increased Fas ligand expression in the tumor tissue and serum of patients with testicular germ cell tumors with seminomatous elements. Urology 2001; 58: 471-476.
174. Baldini E, Ulisse S, Marchioni E, Di Benedetto A, Giovannetti G, Petrangeli E et al. Expression of Fas and Fas ligand in human testicular germ cell tumours. Int J Androl 2009; 32: 123-130.
175. Rzeszutko M, Rzeszutko W, Dziegiel P, Balcerzak W, Kaliszewski K, Bolanowski M. Expression of FAS/APO 1/CD 95 in thyroid tumors. Folia Histochem Cytobiol 2007; 45: 87-91.
176. Owonikoko TK, Hossain MS, Bhimani C, Chen Z, Kim S, Ramalingam SS et al. Soluble FAS ligand as a biomarker of disease recurrence in differentiated thyroid cancer. Cancer 2013; 119: 1503-1511.
177. Lin HC, Lai PY, Lin YP, Huang JY, Yang BC. Fas ligand enhances malignant behavior of tumor cells through interaction with Met, hepatocyte growth factor receptor, in lipid rafts. J Biol Chem 2012; 287: 20664-20673.
178. Liu Q, Tan Q, Zheng Y, Chen K, Qian C, Li N et al. Blockade of Fas signaling in breast cancer cells suppresses tumor growth and metastasis via disruption of Fas signaling-initiated cancer-related inflammation. J Biol Chem 2014; 289: 11522-11535.
179. Nakamoto Y, Kaneko S, Fan H, Momoi T, Tsutsui H, Nakanishi K et al. Prevention of hepatocellular carcinoma development associated with chronic hepatitis by anti-fas ligand antibody therapy. J Exp Med 2002; 196: 1105-1111.
180. Park SM, Rajapaksha TW, Zhang M, Sattar HA, Fichera A, Ashton-Rickardt PG et al. CD95 signaling deficient mice with a wild-type hematopoietic system are prone to hepatic neoplasia. Apoptosis 2008; 13: 41-51.
181. Cai Z, Yang F, Yu L, Yu Z, Jiang L, Wang Q et al. Activated T cell exosomes promote tumor invasion via Fas signaling pathway. J Immunol 2012; 188: 5954-5961.
182. Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z et al. Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res 2006; 12: 3705-3712.